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BASIC INVESTIGATIONS
Complement C5 and Early Oxygen Kinetics during
Murine Sepsis
Gabriel Valencia, J. Vidya Sarma, John G. Younger
Abstract
Objectives: Changes in oxygen consumption (VO2) and
carbon dioxide production (VCO2) are common but poorly
understood features of sepsis. The authors studied the role
of complement C5 in the development of abnormal oxygen
kinetics during sepsis in mice, arguing that as a pro-
inflammatory event, complement activation might exacer-
bate disturbances in oxygen use during abdominal sepsis.
Methods: An open-circuit indirect calorimeter was used to
measure VO2, VCO2, and respiratory exchange ratio during
a seven-day median lethal dose (LD50) murine cecal ligation
and puncture (CLP) model. Results: CLP produced signif-
icant changes in oxygen kinetics within three hours of onset,
although when the animals were stratified by seven-day
survival, no difference in these abnormalities was seen
between the survivors and the nonsurvivors. Genetic
deficiency of C5 did not ameliorate the changes in oxygen
utilization. Rather, the C5-deficient mice experienced more
severe abnormalities in oxygen kinetics and greater mortal-
ity. Treating animals with anti-C5a antibodies at the time of
injury had little effect on oxygen kinetics, indicating that
C5b, rather than C5a, was predominantly acting to protect
the mice during the first 24 hours of illness. Conclusions:
These findings indicate that the primary contribution of C5
to oxygen kinetics during sepsis is salutary through the host
defense conveyed by generation of C5b, rather than
detrimental by worsening oxygen utilization via pro-
inflammatory mechanisms. Key words: open-circuit calorim-
etry; oxygen consumption; respiratory exchange ratio; C5a,
anaphylatoxin. ACADEMIC EMERGENCY MEDICINE
2005; 12:275–281.
Sepsis and septic shock are among the most life-
threatening conditions managed by emergency physi-
cians. The incidence of this condition in the United
States has been estimated to be 751,000 cases per year,
roughly three cases per 1,000 population.1 Many with
the illness will die. Although traditionally deemed
a disease of intensive care units, a recent prospective
study has underscored the fundamental importance
of early recognition and aggressive therapy of this
syndrome in the emergency department (ED).2 A
fundamental component of therapy in that trial was
the early use of mixed-venous oxygen saturation to
gauge oxygen kinetics in critically ill patients.
Oxygen-related metabolic abnormalities are com-
mon in life-threatening infection and occur at multiple
scales throughout the host.3,4 Infection prompts the
proliferation of hematopoietic cell lines renowned for
their respiratory burst. Activated neutrophils and
monocytes/macrophages produce superoxide, hydro-
gen peroxide, hypochlorous acid, nitric oxide, and
peroxynitrite, each consuming oxygen.5 Widespread
endothelial injury leads to loss of capillary integrity
and tissue edema, lengthening the diffusion path from
red blood cells to the mitochondrial inner membrane
of peripheral cells. Mitochondria display a number of
abnormalities that have been reviewed extensively.6
At the organ level, oxygen delivery (DO2) may be
impaired by anemia, myocardial depression, maldis-
tribution of splanchnic blood flow, and widened
ventilation–perfusion inequality in the acutely injured
lung. At the broadest scale, sepsis impacts central
homeostatic mechanisms regulating physical activity
and the wake–sleep cycle, both of which are major
determinants of a host’s oxygen consumption during
acute illness.7 To further complicate matters, in many
septic patients, a so-called hypermetabolic state may
eventually occur, although differences in oxygen
consumption between septic patients with and with-
out hypermetabolic features are subtle (about twofold)
comparedwith differences between septic patients and
normal humans performing daily activities such as
exercise (about 12-fold).8
The net abnormality under these circumstances is
usually decreased oxygen content in blood returning
to the heart from distal vascular beds. As the utility of
monitoring mixed or central venous oxygen content
and devising therapies capable of improving it under-
goes intense scrutiny in clinical trials, much remains
unknown about the events leading to abnormal
oxygen kinetics. It has long been recognized that
lipopolysaccharide (LPS, an important structural
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constituent of the outer leaflet of the outer membrane
of gram-negative bacteria) and, to a lesser extent,
lipoteichoic acid (a similar part of the gram-positive
cell wall) can precipitate many of the clinical features
of sepsis in the absence of actual infection.9,10 These
and other molecules set into motion a cascade of
events that ultimately produce the clinical phenome-
non of sepsis, including impaired oxygen kinetics. Yet
the intermediate steps in this disease pathway remain
obscure.
In the current study we explored the relationship
between impaired oxygen kinetics and life-threaten-
ing infection using a mouse model of polymicrobial
abdominal sepsis, namely, cecal ligation and puncture
(CLP). Specifically, we studied the contribution of the
complement cascade as a link in the development of
abnormal oxygen kinetics. The complement cascade
and, in particular, the mannose-binding lectin and
alternative pathways are constitutively expressed
and activated within seconds of exposure to gram-
negative or gram-positive bacteria. Central features of
complement activation in this setting are rapid opso-
nization of bacterial surfaces by activated C3 (needed
for optimal phagocytosis by neutrophils and macro-
phages), assembly within the bacterial cell wall of the
membrane attack complex (MAC), which, in some
instances, may be directly bactericidal, and release of
small peptides (C5a and C3a) that serve as potent
activators of cellular immunity. The role of comple-
ment in sepsis has been described in several recent
reviews.11,12
Although many proteins contribute to complement
activation, C5 occupies a pivotal position. Cleavage of
C5 produces C5b, which initiates assembly of bacteri-
cidal MAC, and C5a. The role of C5a in life-threatening
infection is complex. In the setting of gram-negative
pneumonia, failure to generate C5a or the absence of
the C5a receptor leads to an abnormal inflammatory
response and increased mortality.13,14 But in models of
abdominal sepsis, C5a production may be so robust as
to harm the host.15 Widespread, dysregulated comple-
ment activation has been documented to produce
deleterious effects on oxygen-dependent systems at
the subcellular, cellular, and organ levels. Intravascular
complement activation causes hypotension, metabolic
acidosis, and loss of endothelial integrity in the lung
and the gut.16 Strategies that block C5a’s effects have
been shown to preserve neutrophil function, correct
coagulation abnormalities, and improve survival in
polymicrobial sepsis.15,17–19
The specific contribution of complement, or to the
best of our knowledge, any innate immune pathway,
to oxygen kinetics during sepsis has not been dem-
onstrated, although it is reasonable to suspect a con-
nection. A link between immunologic events and
clinical phenomena such as altered oxygen demand
may lead to new therapies or generate further
enthusiasm for strategies under study (such as anti-
C5a treatment). In this study we examined the re-
lationship between C5 and abnormal oxygen kinetics
following CLP in mice. Using an open-circuit calo-
rimeter, we characterized oxygen consumption, car-
bon dioxide production, and the respiratory exchange
ratio (VO2, VCO2, and RER, respectively) after CLP
and correlated changes with seven-day mortality.
Next, the role of C5 in these metabolic changes was
considered. We argued that if C5 was involved,
a distinct oxygen kinetics phenotype might be ob-
served in animals genetically deficient in C5. Specif-
ically, if C5 linked peritoneal contamination with
the development of oxygenation abnormalities, C5-
deficient animals might demonstrate less severe abnor-
malities. Furthermore, an argument in support of
a role of C5 would be strengthened if, in the absence
of fecal contamination of the abdomen, sterile in-
traperitoneal complement activation reproduced the
oxygen kinetic abnormalities seen in sepsis. Lastly, to
specifically address differential contributions of C5a
and C5b, we also studied animals in which a function-
blocking antibody directed against C5a had been
administered at the time of injury.
METHODS
Study Design. This was a laboratory investigation of
abdominal sepsis using a well-established murine
model. Sepsis was induced by CLP. Animal protocols
were approved by the institutional committee on the
use and care of animals, and animal handling con-
formed to existing regulatory policies on the use of
animals in science.
Animal Preparation. Specific-pathogen-free ICR-
strain outbredmicewere obtained fromHarlan Sprague
Dawley, Indianapolis, Indiana. C5-deficient mice,
B10.D2-Hc0 H2d H2-T18c/oSnJ and their control
strains, B10.D2-Hc1 H2d H2-T18c/nSnJ (hereafter re-
ferred to as C52/2 and C51/1) were obtained from
Jackson Laboratories, Bar Harbor, Maine. The C52/2
strain is homozygous for a naturally occurring two
base-pair deletion in the 5# end of the C5 open
reading frame resulting in a premature stop codon
and a nonfunctional protein.20,21 Reagents were
obtained from Sigma Chemical Co., St. Louis, Mis-
souri, unless otherwise noted.
Study Protocol.
Metabolic Measurements. The VO2 and VCO2 were
measured using an indirect open-circuit calorimeter
(Oxymax Deluxe, Columbus Instruments, Columbus,
OH) that contained eight sealed cages and provided
measurements every 30 minutes for each cage. The
VO2 and VCO2 were determined by the difference
in contents of each gas between the cage inlet and
exhaust, with an electrochemical method used for
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measurement of O2 and an infrared spectroscopic
method for CO2. The RER was calculated as VCO2/
VO2. Mice were weighed and placed in individual
chambers with rodent chow (Labchow 5001, Purina
Mills, Richmond, IN) and a water substitute (Napa
Nectar, SE Lab Group, Maiden, NC) the day prior to
the experiment. A six-hour initial measurement
served as a baseline control for each animal. Experi-
ments were always started in late afternoon to control
for circadian fluctuations in activity and metabolism.
Cecal Ligation and Puncture (CLP). Mice were anes-
thetized with isoflurane in oxygen (Abbott Critical
Care, North Chicago, IL). A 1-cm incision was made
in the abdomen. The cecum was externalized and
ligated below the ileocecal valve, and a 20-ga needle
was passed through and through. The cecum was
returned and the abdomen was closed in two layers.
This produced a seven-day median lethal dose (LD50)
model in ICR mice.
Anti-C5a Antibody. Affinity-purified polyclonal goat
immunoglobin G (IgG) raised against the C-terminus
of rat C5a (CTIADKIRKESHHKGMLLGR) was pro-
duced as described.18 Cross-reactivity with murine
C5a has been shown previously in a mouse CLP
model.22 Mice receiving treatment with the antibody
were administered 40 mg in 100 mL of saline via tail-
vein injection at the time of CLP.
Sterile Peritoneal Inflammation. In some experi-
ments, cobra venom factor (CVF) was used to produce
intra-abdominal C5 activation in the absence of fecal
contamination of the peritoneal cavity. CVF, which
forms a stable C3/C5 convertase with factor B and
catalyzes sustained and unregulated cleavage of C3
and C5, was purified from raw venom using anion
exchange chromatography as described.23 Contami-
nating LPS in the purified protein was reduced using
a polymyxin-B column (Detoxigel, Pierce, Rockford,
IL). Residual LPS content was measured with a Lim-
ulus assay (Associates of Cape Cod, Falmouth, MA)
and found to be 0.4 ng/unit CVF. To produce com-
plement activation, the animals received 30 units/kg
CVF in 90 mL of saline intraperitoneally, a dose known
to produce extensive activation in mice.14 As trace
amounts of LPS were detectable in this material, an
LPS-balanced vehicle was prepared using equal
amounts of LPS in saline.
In additional experiments, sterile endotoxic perito-
nitis was induced with intraperitoneal injections of 80
or 400 mg of LPS in sterile saline.
Data Analysis. Values were reported as mean 6
standard deviation. Changes in VO2, VCO2, and RER
over time within each group were analyzed with
analysis of variance (ANOVA) followed by Dunnett’s
test for comparison of each time point with the time
0 value. Differences between groups (e.g., VO2 trends
between C51/1 and C52/2 animals) were analyzed
using repeated-measures ANOVAwith post-hoc com-
parisons made using the Tukey multiple comparisons
correction. Survival analysis was done with a pro-
portional hazards model as we have described pre-
viously.24
RESULTS
VO2, VCO2, and RER Are Significantly Depressed
by CLP. All measured oxygen kinetic parameters
decreased significantly within three to six hours of
CLP (p , 0.01, Figure 1). In particular, RER decreased
from 0.85 to approximately 0.7, suggesting a change in
metabolic substrate from carbohydrate to lipid early
in the course of illness. While no death was seen in the
first 24 hours, eight of 20 ICR-strain mice died within
seven days of injury. When the animals were stratified
by seven-day survival, no difference in VO2, VCO2, or
RER over the first 24 hours was observed. Thus,
although CLP produced rapid derangement in oxy-
gen kinetics, the severity of these changes over the
first 24 hours did not predict survival.
C5 Deficiency Worsens Oxygen Kinetics and
Increases Lethality. When C51/1 and C52/2 mice
(both on the B10.D2, rather than ICR, genetic back-
ground) were subjected to CLP, both groups dis-
played more severe early abnormalities than
similarly injured ICR mice (Figure 2). The VO2 and
VCO2 were significantly worse in ill C5-deficient
animals. Importantly, 75% of the C52/2 animals
died during the first 24 hours of injury, compared
with no death in the C51/1 group (p , 0.05).
Accordingly, most of the animals in the C52/2 group
were moribund before the conclusion of the 24-hour
data-collection period. This may explain swings in
observed RER in this group, with some individuals
demonstrating an RER > 1.0. This difference in re-
sponse to infection underscores the importance of C5
in early host defense. Rather than ameliorating oxy-
gen kinetic abnormalities during abdominal sepsis,
the absence of C5 led to an accelerated course with
greater abnormalities in VO2, VCO2, and RER.
Anti-C5a Antibody Has Only a Modest Effect on
Calorimetry during Sepsis. In parallel experiments
using ICR-strain mice treated with function-blocking
polyclonal IgG directed against the C-terminal of C5a,
no difference in VO2 or VCO2 was noted between the
treated and untreated mice with sepsis. However, the
anti-C5a-treated mice demonstrated a statistically de-
tectable but transient diminution in RER when com-
pared with the untreated mice (Figure 2). The
significance of this observation is uncertain, given
that no change in VO2 or VCO2 was statistically
detectable.
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Intraperitoneal Complement Activation Does Not
Mimic CLP. Intraperitoneal activation of C5 using the
C3:C5 convertase CVF produced changes in oxygen
kinetics distinct from CLP (Figure 2).
In summary, the complement-related experimental
results indicate a central role for C5 in survival during
CLP. Rather than leading to worsened oxygen utili-
zation in early sepsis, the presence of C5 somewhat
ameliorated these abnormalities and was highly pro-
tective against early mortality. As anti-C5a treatment
did not increase mortality or dramatically affect
oxygen kinetics, these data point to C5b (and, by
inference, the MAC) as being the predominant pro-
tective component of C5 in the first hours of injury.
Sterile LPS-induced Peritonitis Produces Calori-
metric Abnormalities Similar to CLP. Unlike sterile
intra-abdominal complement activation, intraperito-
neal administration of LPS was associated with a rapid
fall in VO2, VCO2, and RER that closely resembled the
changes seen following CLP, particularly at the 400-mg
dose (Figure 3). We interpret these findings as in-
dicating that while intraperitoneal complement acti-
vation was not observed to mimic the changes in
oxygen kinetics seen during intra-abdominal infec-
tion, other immune pathways (in this case, presum-
ably the LPS-binding protein/CD14/Toll-like receptor
system) were capable of reproducing the effects of
peritoneal soilage.
DISCUSSION
Innate recognition of extraluminal bacteria is an
important early step in host defense against life-
threatening intra-abdominal infections, and a number
of strategies are constitutively in place to carry out
this task. In the current study, we hypothesized that
important global physiologic responses to infection,
namely, changes in VO2, VCO2, and RER, might be
linked to triggers in the complement cascade. The
picture that emerges from the data is complex. C5 is
a crucial component of host defense early in the
course of injury. Its absence worsens the oxygen
kinetic abnormalities produced by the model and,
more importantly, markedly increases the lethality of
CLP. As C5 plays two roles in host defense—initiation
of MAC formation and release of C5a—we were
interested in whether the defect in the C5-deficient
animals could be tied to one role or the other. We
found that treatment with a polyclonal function-
blocking IgG directed against the C-terminal of C5a
had only very modest effects on the oxygenation
parameters and did not lead to early deaths, suggest-
ing that the other central function of C5—assembly of
MAC—is predominant.
Our results demonstrated striking changes in oxy-
gen kinetics within hours of intra-abdominal injury. A
clear role for C5 emerged, but not as expected; the C5-
deficient mice experienced significantly greater mor-
tality and had more severe derangements in oxygen
kinetics than the C5-sufficient mice after injury. These
abnormalities were distinctly different from those
induced by sterile intraperitoneal complement activa-
tion. The differential responses to injury among
normal mice and those treated with anti-C5a were
modest and not sustained, suggesting that C5b, and
not C5a, was necessary for host survival.
The current data reinforce the importance of dis-
tinguishing between C5b and C5a when evaluating
Figure 1. Changes in oxygen consumption (VO2), carbon
dioxide production (VCO2), and respiratory exchange ratio
(RER) in the first 24 hours following cecal ligation and puncture
stratified by seven-day survival. Values represent the mean 6
standard deviation from 12 survivors and eight nonsurvivor ICR-
strain mice. Although each parameter changed significantly
from pre-injury and baseline time points (p , 0.05 for each),
there was no difference noted between the survivor and
nonsurvivor groups. *p , 0.05 for survivors compared with
time 0; #p , 0.05 for nonsurvivors compared with time 0.
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models of infection. C5b is required for assembly of
a directly antibacterial defense (MAC). C5a is a chemo-
attractant and proinflammatory mediator and thus
impacts bacterial killing only indirectly by attracting
and stimulating professional phagocytes. The contri-
butions of C5a to defense may differ by site. The
beneficial effects of C5 in life-threatening infection has
been demonstrated by our group and others in studies
of gram-negative pneumonia caused by Pseudomonas
aeruginosa.24–26 Yet in models of intra-abdominal in-
fection, presumably polymicrobial in origin and eli-
cited by normal flora allowed access beyond their
normal confines, anti-C5a therapy has been shown to
improve a number of parameters in murine abdom-
inal sepsis, most importantly, survival.15,17–19,22,27
These disparate findings may reflect differences be-
tween the bacterial adversaries present in the pneu-
monia and abdominal sepsis models or more
fundamental differences between immunity within
the peritoneum and at a mucosal surface.
Greater understanding of the role of C5 in life-
threatening infections and in shock has recently re-
ceived significant interest due to ongoing development
of anticomplement strategies currently in clinical trials.
Of particular interest to our group are those studies
examining anti-C5 treatment in ischemia–reperfusion-
associated conditions and cardiopulmonary bypass
(CPB). CPB shares some common features with sepsis
as a result of extensive activation of innate humoral
immune pathways by blood contacting artificial surfa-
ces within the perfusion apparatus. Recent work with
pexelizumab, a monoclonal antibody that conceals the
C5a–C5b cleavage site on the C5 molecule and thus
prevents its activation, indicates a reduced risk of 30-
day perioperative myocardial infarction and mortality
following CPB.28 Clinical studies with this and other
agents taking aim at the complement system are
currently under way for a number of inflammatory
conditions. A central issue will be how best to balance
the potent anti-inflammatory effects of these agents
with consequences theymayhave onhost defense. This
challenge is likely to be particularly difficult in the
emergency setting, where inflammatory and infectious
diseases may exhibit considerable clinical overlap and
may be difficult to rapidly distinguish from one
another. How targeted interference with the comple-
ment cascade, in infectious and noninfectious inflam-
matory conditions, ultimately finds its way into the
emergency medicine arsenal is a question likely to see
preliminary answers in the next five years.
Figure 2. Role of complement C5 in oxygen kinetic changes in sepsis. A. Metabolic response to sterile intra-abdominal complement
activation using cobra venom factor (CVF). C5 activation did not produce the characteristic decline in each parameter seen with
cecal ligation and puncture (CLP) (#p , 0.05 for vehicle-treated animals compared with baseline). i.p. = intraperitoneal. B. Oxygen
kinetics in C5-sufficient (C51/1) and C5-deficient (C52/2) animals following CLP. Compared with the C5-sufficient animals, the C5-
deficient mice displayed significantly worse oxygen consumption (VO2) and carbon dioxide production (VCO2). The wide swings
seen in the respiratory exchange ratio (RER) in the C52/2 animals were likely related to the fact that 75% of these animals became
moribund and died over the observation period (p , 0.05 by proportional hazards analysis). (*p , 0.05 compared with baseline for
C51/1; #p , 0.05 for C52/2). C. Effect of anti-C5a antibodies. Anti-C5a was associated only with a small difference in RER between
the untreated and treated mice. (*p , 0.05 compared with baseline for untreated control animals; #p , 0.05 for mice treated
intravenously with anti-C5a polyclonal immunoglobin G prior to injury.) n $ 4 animals per condition in all experiments.
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LIMITATIONS
To the best of our knowledge, this is the first report
to consider immune system genetic determinants of
calorimetric behavior during sepsis in mice. Indirect
calorimetry is a useful technique for evaluating
metabolic changes in rodent models of life-threaten-
ing disease during which the prolonged anesthesia
needed for invasive methods may be harmful. A
limitation of the method is the difficulty with which
a relatively hypermetabolic state might be identified if
present in septic animals. Calorimetric measures in
unanesthetized mice will reflect not just changes in
metabolism, but also changes in activity (although the
observed changes in RER in the current study indicate
that the measured phenomenon was more than an
indirect assessment of the animals’ tendency to
huddle during acute illness). In many septic patients,
an early fall in VO2 may be followed by a relative
hypermetabolic state. The increased oxygen consump-
tion occurring in this state may, particularly when
acute lung injury is also present, pose a significant
challenge to caregivers. However, regardless of the
presence or absence of hypermetabolism, the amount
of oxygen consumed in sepsis is much smaller than is
consumed in many activities performed in daily life.
In the experimental conditions imposed by indirect
calorimetry, particularly when uninjured animals
serve as controls, relative hypermetabolic conditions
are difficult to detect, and our methodology could not
evaluate the role of complement in the hypermeta-
bolic response that is often seen in sepsis and septic
shock.
CONCLUSIONS
Cecal ligation and puncture in mice produces a path-
ologic signature of abnormalities in VO2, VCO2, and
RER as measured with an open-circuit indirect calo-
rimeter. The role of C5 in these changes in this mouse
model appears to be related to protective effects of
C5b rather than to aggravating effects of C5a activa-
tion.
The authors thank Janet Hoff and the Center for Integrative
Genomics at the University of Michigan for their assistance with
the calorimeter.
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